Scancell Holdings plc has agreed to acquire Neuphoria Therapeutics Inc. in an all-share merger designed to establish a Nasdaq-listed biotechnology company and finance a registrational Phase 3 study of iSCIB1+ in advanced melanoma. The combined company plans to operate as Scancell and apply to trade on Nasdaq under the proposed ticker SCLT while retaining Scancell’s existing AIM listing in London. Scancell expects the merger, equity placements, proposed debt financing and Neuphoria Therapeutics’ remaining cash to provide up to $89 million of funding. The capital is intended primarily to carry the iSCIB1+ program through its planned Phase 3 primary readout in the second half of 2028 and extend the combined company’s cash runway into 2029. The transaction remains subject to shareholder, regulatory, financing and Nasdaq-listing conditions and is expected to close in late 2026.
How the Scancell and Neuphoria Therapeutics merger supports a Phase 3 iSCIB1+ melanoma trial
Scancell is developing iSCIB1+ as an off-the-shelf DNA active immunotherapy intended to stimulate immune responses against several melanoma-associated antigens. The treatment is being studied with the checkpoint inhibitors nivolumab and ipilimumab in patients with advanced unresectable melanoma through the Phase 2 SCOPE study. Scancell has said the United States Food and Drug Administration has cleared the investigational new drug application for a Phase 3 study and granted iSCIB1+ Fast Track designation.
The merger addresses a problem familiar to many smaller European biotechnology companies: promising clinical results do not automatically provide enough capital to run a global registrational study. Scancell’s proposed Nasdaq listing is intended to expand access to United States healthcare investors and create a more liquid public-market structure for future fundraising. Neuphoria Therapeutics already has a Nasdaq listing, making its corporate structure strategically valuable even though Scancell does not plan to develop most of Neuphoria Therapeutics’ internal assets after closing.
Scancell expects to secure $39.1 million through a private placement, approximately $12 million through a United Kingdom institutional placing and up to $3 million through a retail offer. The company has also signed a non-binding term sheet with funds managed by BlackRock for as much as $25 million in secured debt financing. At least $10 million of Neuphoria Therapeutics’ cash must remain available at closing, bringing the proposed total financing package to as much as $89 million.
Not all of that amount is guaranteed. The BlackRock debt proposal remains subject to due diligence, definitive agreements and shareholder approval, while the United States listing transactions require at least $75 million of financing to be secured. The merger also needs approval from both companies’ shareholders, effectiveness of a Form F-4 registration statement and approval for Scancell’s American depositary shares to trade on Nasdaq.
Scancell expects a pro forma net cash position of approximately $79.1 million before transaction costs if the proposed financing and merger are completed. Management believes that amount can support the iSCIB1+ Phase 3 program through its primary readout and maintain operations into 2029. The actual runway will depend on patient recruitment, site costs, manufacturing requirements, debt drawdowns and the development spending allocated to Scancell’s other immunotherapy programs.
What Scancell’s 77% progression-free survival result does and does not establish
Scancell reported that patients receiving iSCIB1+ with nivolumab and ipilimumab achieved a progression-free survival rate of 77% at 22 months in the Phase 2 SCOPE study. The company described the response as durable and said further progression-free survival and overall survival data are expected during the next 12 months. These findings underpin the decision to move the program toward a randomized registrational trial.
The SCOPE study is an open-label, multicohort Phase 2 trial evaluating SCIB1 or iSCIB1+ with approved checkpoint inhibitors in advanced unresectable melanoma. Its purpose includes assessing the safety and activity of adding Scancell’s immunotherapy to nivolumab and ipilimumab or pembrolizumab. The study design can identify clinically encouraging response and survival patterns, but the absence of a concurrently randomized control group limits the conclusions that can be drawn about the precise contribution of iSCIB1+.
Patients receiving combination checkpoint therapy can already experience durable responses, and differences in baseline disease characteristics, follow-up periods and patient selection can affect comparisons with historical data. The Phase 2 results therefore support further testing rather than establishing that iSCIB1+ improves survival over nivolumab and ipilimumab alone.
The planned Phase 3 trial is expected to provide the more definitive comparison needed for regulatory review. A randomized study should help determine whether adding iSCIB1+ produces a statistically and clinically meaningful improvement while maintaining an acceptable safety profile. Scancell has indicated that the Phase 3 study could begin during the third quarter of 2026, subject to financing and operational readiness.
iSCIB1+ is designed as an active immunotherapy rather than a personalized treatment manufactured separately for each patient. That off-the-shelf approach could simplify production and distribution compared with individualized cancer vaccines if the product ultimately demonstrates efficacy. The treatment would still need to establish manufacturing consistency, appropriate delivery and sufficient commercial differentiation from other immunotherapy combinations being developed for melanoma.
The regulatory path is more advanced than it was a year earlier because the United States Food and Drug Administration has granted Fast Track designation and cleared the Phase 3 investigational new drug application. Fast Track status can provide more frequent regulatory communication and potential eligibility for accelerated review mechanisms, but it does not lower the requirement to produce adequate evidence of safety and efficacy.
Why the Nasdaq listing and financing structure bring both opportunity and dilution
Existing Scancell shareholders are expected to own approximately 85.5% of the combined company and existing Neuphoria Therapeutics shareholders approximately 14.5% immediately after applying the agreed merger ownership split. After accounting for the broader financing structure, Neuphoria Therapeutics stockholders are expected to hold approximately 13.7% of Scancell’s enlarged voting ordinary share capital and approximately 11.1% of total capital when non-voting shares are included.
Each outstanding Neuphoria Therapeutics share is expected to convert into approximately 37.77199 Scancell American depositary shares, subject to the merger terms and adjustments. Scancell plans a ten-for-one consolidation of its ordinary shares before closing, while each American depositary share is initially expected to represent ten consolidated ordinary shares. The restructuring is intended to produce a Nasdaq trading price and share structure more consistent with United States market conventions.
The financing will materially increase Scancell’s share count. The $39.1 million private placement alone is expected to involve more than 324 million new ordinary and non-voting shares before the proposed consolidation, while the United Kingdom placing and retail offer will add further equity. Existing shareholders gain a funded Phase 3 strategy and Nasdaq access, but their percentage ownership will be diluted by the new capital required to execute it.
The proposed BlackRock facilities add another layer of risk and flexibility. The debt would be drawn in as many as four tranches through December 2027, with an initial interest-only period followed by principal and interest repayments. Part of the debt may be convertible into equity, and the lender is expected to receive warrants linked to the amounts drawn. These provisions could reduce the need for immediate additional equity but may create interest expense and further dilution later.
Neuphoria Therapeutics shares rose to approximately $3.92 on July 23, an increase of about 17% from the previous close, after trading as high as $4.36. The reaction indicates that investors assigned value to the Scancell equity consideration and the contingent rights attached to Neuphoria Therapeutics’ partnered assets. The stock remained below the $4.75 per-share cash proposal that Neuphoria Therapeutics disclosed receiving from Lynx1 Master Fund in December 2025, although the merger offers participation in Scancell’s future oncology value rather than a fixed cash exit.
The transaction is not a conventional combination of two operating pipelines. Neuphoria Therapeutics had reduced its workforce to one employee, terminated facility leases and paused or cancelled most research activities while pursuing a strategic transaction. Its cash, Nasdaq listing and partnered-asset economics are more important to the merger than its ability to contribute an independently funded development organization.
What happens to Neuphoria Therapeutics’ BNC210 and partnered drug programs after the merger
Neuphoria Therapeutics previously positioned BNC210 as its lead neuropsychiatric therapy, but development changed after the AFFIRM-1 Phase 3 trial in social anxiety disorder failed to meet its primary and secondary endpoints in October 2025. The company halted development in social anxiety disorder and began a strategic review that eventually led to the proposed Scancell transaction.
Scancell has said it does not intend to develop Neuphoria Therapeutics’ non-partnered assets beyond minimal costs required to maintain and enforce relevant agreements and intellectual property. The combined company will instead concentrate its resources on iSCIB1+ and Scancell’s existing ImmunoBody and Moditope pipeline. This means the merger is unlikely to revive BNC210 as a major internally funded clinical program unless the asset is separately licensed or monetized.
Neuphoria Therapeutics shareholders will receive contingent value rights alongside their Scancell shares. These rights entitle holders to potential future payments linked to partnered programs, including the company’s collaboration with Merck & Co., economics related to the KAT6 program licensed to Pfizer Inc., certain intellectual-property monetization proceeds and an Australian research and development tax credit.
The contingent value rights allow Neuphoria Therapeutics shareholders to retain exposure to assets that Scancell does not consider central to its operating strategy. Merck & Co. has been developing MK-1167 through a partnered program involving the alpha-7 nicotinic acetylcholine receptor, while Neuphoria Therapeutics received an Australian dollar 1.416 million distribution in May 2026 after Pfizer Inc. initiated a Phase 3 trial involving the partnered KAT6 program.
Payments under contingent value rights are uncertain and depend on future milestones, licensing receipts, development decisions by partners and allowable deductions. They should therefore be viewed as potential additional consideration rather than guaranteed merger value.
For Scancell, the transaction is primarily a route to capital, Nasdaq and Phase 3 execution. For Neuphoria Therapeutics, it offers shareholders continued participation in a late-stage oncology program after the company’s own lead asset failed in Phase 3 and internal development was largely suspended.
The clinical significance will ultimately depend on whether the financing closes and whether the randomized iSCIB1+ trial confirms the durability suggested by SCOPE. A successful Phase 3 program could validate Scancell’s off-the-shelf cancer immunotherapy strategy and justify the complexity and dilution associated with the transaction. Failure to reproduce the Phase 2 results would leave the combined company with debt, a substantially expanded share base and limited value from the Neuphoria Therapeutics assets it does not plan to develop.
